Trials / Completed
CompletedNCT00319254
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKI-606 (Bosutinib) | SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression. |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2006-04-27
- Last updated
- 2013-01-31
- Results posted
- 2013-01-31
Locations
15 sites across 8 countries: United States, Australia, France, Hong Kong, Malta, Poland, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00319254. Inclusion in this directory is not an endorsement.